Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) most recently reported quarterly actual earnings per share of $-3.14 for the period ending on 2016-06-30. Prior to the company reporting, consensus estimates based on data from Zacks Research projected the company to report EPS of $-3.76. The difference between the estimate and the actual EPS was $0.62 creating a surprise factor of 16.49%. Currently, the company has an impact score of 0. The likelihood that the stock will move on news is greater with a higher impact score. According to Beta Research, the stock has a sentiment score of 0. On a scale between 1 and -1, a positive score tends to portray a favorable view of company results by news outlets. The opposite is true for a negative sentiment score.
In taking a look at where the stock might be headed, analysts have a consensus price target of $188.1 on the shares. The most bullish brokerage firm has a $332 target, while the most bearish sees the stock headed towards $60. This is according to the 10 estimates taken into consideration by Zacks Research.
In terms of Buy/Sell recommendations, analysts have a consensus rating of 2.1. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were 10 recommendations taking into account in order to arrive at this number. Of the 10, 8 have a Strong Buy rating and 0 are rating it a Buy.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company’s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. It is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial, that serves as the basis for seeking regulatory approval in the United States and Europe. As of December 19, 2012, the Company completed enrollment of the POISE trial with 217 patients.
Intercept Pharmaceuticals, Inc. - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.